Meet us at BIO Europe Spring 2021

Meet Sciomics at Bio Europe Spring - Focus: COVDI-19 Disease Severity Biomarkers

scioDiscover - Protein Expression Analysis Platform

Our scioDiscover service enables high-content, immuno-based analysis of various biological samples leading to a comprehensive overview of proteomic changes. Key pathways in various diseases such as cancer, neurological disorders and organ failure are covered. The technology was successfully applied in a variety of biomedical studies and to discover new biomarker signatures. Within the analysis, 1,300 proteins are analysed in parallel. The scioDiscover protein array based service enables fast and targeted research while still offering a broad overview of potential changes on the protein level in your samples. 

 

Application Sample types - Sample requirement Advantages Service includes
       
Signalling Pathway Profiling plasma/serum - 10 ul high-content sample preparation
Immunsystem activation marker profiling tissue - 50 mg 1030 proteins analysed protein extraction
Transcription factor analysis  cells - 5 million   protein concentration measurements
Cancer pathway screening cerebrospinal fluid - 30 ul broad coverage of:  protein quality control
Cell surface marker Profiling cell culture supernatant - 10-20 ml - signalling pathway proteins  
Profiling of apoptotic processes/ apoptosis pathway analysis    - transcription factors sample labelling
  others on request - apoptosis marker sample purification
Disease mechanism profiling   - markers for oxidative stress sample incubation on arrays
Pathway activation in stem cells    - cell surface markers  
Analysis of organ damage/failure models    - cytokines/chemokines raw data acquisition
Response of cells and tissue models to oxidative stress analysis     data normalisation
Profiling proteomic changes for various cell culture conditions   minimal sample requirements data analysis
    native matrixes (non-fractionated/non-depleted) statistical analysis
Molecular initiate event analysis   sensitivity as ELISA or better comprehensive study report
Compound mode-of-action analysis      
Prediction markers for toxicological effects    fully immuno-based assay  
       
Biomarker Discovery   Reliable dual-colour study design  
Drug Target Discovery   high reproducibility, CV < 10%  
       
CD cell surface molecule expression in immune cells        

 

Target coverage - GO annotations

Biological Process Cellular Component Protein Classes 
cellular process (GO:0009987) 438 cell part (GO:0044464) 172 signaling molecule (PC00207) 122
metabolic process (GO:0008152) 410 organelle (GO:0043226) 97 receptor (PC00197) 113
response to stimulus (GO:0050896) 228 extracellular region (GO:0005576) 60 nucleic acid binding (PC00171) 109
biological regulation (GO:0065007) 220 membrane (GO:0016020) 59 hydrolase (PC00121) 77
developmental process (GO:0032502) 172 macromolecular complex (GO:0032991) 47 transcription factor (PC00218) 71
immune system process (GO:0002376) 145 extracellular matrix (GO:0031012) 28 enzyme modulator (PC00095) 67
localization (GO:0051179) 116 cell junction (GO:0030054) 3 cell adhesion molecule (PC00069) 62
multicellular organismal process (GO:0032501) 72 synapse (GO:0045202) 2 defense/immunity protein (PC00090) 52
apoptotic process (GO:0006915) 67     cytoskeletal protein (PC00085) 40
cellular component organization or biogenesis (GO:0071840) 65     oxidoreductase (PC00176) 31
biological adhesion (GO:0022610) 60     kinase (PC00137) 31
reproduction (GO:0000003) 26     transporter (PC00227) 27
locomotion (GO:0040011) 4     transfer/carrier protein (PC00219) 25
        calcium-binding protein (PC00060) 20
        phosphatase (PC00181) 20
        structural protein (PC00211) 18
        extracellular matrix protein (PC00102) 17
        cell junction protein (PC00070) 17
        membrane traffic protein (PC00150) 14

PLEASE NOTE: GO annotation terms may overlap 

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Reference customers:

Prof. Dr. Faikah Güler, Medical School Hanover, Germany

Julian Kamhieh-Milz, Charite, Berlin, Germany

 

Case study - Bladder Cancer

Case study - Acute Kidney Injury

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

Testimonials

"The quality of the data we have obtained is exceptional."

 

Prof. Claudio Mauro
Birmingham University, Institute of Inflammation and Ageing, Birmingham, UK

"We have performed an acetylation array on primary T lymphocytes with Sciomics. The quality of the data we have obtained is exceptional. They have a model of collaboration with the team conducting the experiment. This means they generate the data and assist with further analyses of the data. The screening has opened up several exciting ways forward for us."

Product: scioAcetyl protein and protein acetylation profiling service (under co-development with selected partners)

 

Tweets